CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We have now added a new section called the "Assay History List" to the "At A Gla...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...